Rafa Laboratories To Expand Into Innovative Products For Export Growth

Israeli drugmaker Rafa Laboratories' recent decision to gradually move away from being a generic drugmaker and begin investing in the research and development (R&D) of patented medicines underlines a key global trend which BMI has previously highlighted. Despite the imminent patent cliff in 2011 - which should cause a surge in generic drug sales, particularly in the emerging markets where demand will be highest - we expect generic pharmaceutical firms to diversify into innovative medicines to maintain high margins, increase revenues and buffer against more intense competition.

To read the full article, please choose one of the following options: